Center for Translational Viral Oncology (CTVO)

转化病毒肿瘤学中心 (CTVO)

• 批准号: 10223341
• 负责人: Krzysztof Reiss
• 金额: $ 197.78万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-15 至 2022-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10223341
• 关键词: Academic Medical Centers; Academic support; Address; Advisory Committees; Affect; African American; Area; Basic Science; Biological; Biomedical Research; Cell Cycle Regulation; Cell physiology; Cells; Centers of Research Excellence; Cervical; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collaborations; Core Facility; Country; Cytomegalovirus; Data; Death Rate; Development; Diagnostic; Disease; Endogenous Retroviruses; Ensure; Extramural Activities; Funding; Future; Gene Expression Regulation; Genome; Goals; HIV; HIV Infections; Head and Neck Cancer; Health; Health Sciences; Healthcare; Hepatitis B Virus; Hepatitis C virus; Homeostasis; Human; Human Herpesvirus 4; Human Herpesvirus 8; Human Papillomavirus; Immune; Immune response; Incidence; Infrastructure; Institution; Interdisciplinary Study; International; JC Virus; Joints; Kaposi Sarcoma; Knowledge; Laboratories; Laboratory Research; Leadership; Louisiana; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of liver; Mentors; Mentorship; Minority Groups; Molecular; Morbidity - disease rate; Not Hispanic or Latino; Oncogenic; Oncogenic Viruses; Oncology; Pathogenesis; Patients; Population; Program Development; Public Health; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resources; Role; Sampling; Scholarship; Scientist; Signal Transduction; Teacher Professional Development; Training; Training Support; Translating; Translational Research; United States National Institutes of Health; Universities; Viral; Virus; Virus Diseases; Vulnerable Populations; Work; base; biobank; biological systems; carcinogenesis; career; clinical care; clinical infrastructure; clinical material; clinical translation; co-infection; design; epigenetic regulation; experience; health disparity; high risk; interest; leadership development; metropolitan; mortality; neurotropic; novel; novel diagnostics; novel therapeutic intervention; patient population; prevent; primary effusion lymphoma; programs; treatment strategy; tumor; virus host interaction; virus related cancer

Abstract: The primary goal of this COBRE is to strengthen the biomedical research infrastructure in Louisiana by training Promising Junior Investigators (PJIs) who can develop independent research addressing a major health problem in our region. Virus-associated cancers remain a major cause of morbidity and mortality in our region and disproportionately affect the African American population. These include HPV- associated cervical, anogenital, and head and neck cancers, KSHV-associated Kaposi sarcoma and primary effusion lymphoma, HCV- and HBV-associated liver cancers and others, all which are unusually highly prevalent in our area. Increases in these diseases may be explained, in part, by the large number of HIV-infected patients in the region. In addition, our data also indicate that co-infection of cells with more than one virus promotes or associates with malignant transformation. Therefore, understanding how particular viruses and viral co- infections promote the development of malignancies is essential to identifying and implementing new preventative, diagnostic and treatment strategies. It follows that training a new cadre of investigators capable of conducting novel research in the field of viral oncology is essential for our state. This will be accomplished by developing a Center for Translational Viral Oncology (CTVO) that leverages existing resources in order to train new investigators, develops novel laboratory infrastructure, and supports research projects designed to study these diseases in our unique populations. The CTVO will support the scientific, mentoring and administrative needs of the PJIs by providing (i) experienced mentoring teams composed of NIH-funded and internationally recognized investigators who are committed to guiding PJIs in developing cutting edge research, ensuring their successful training, and supporting their development as independent researchers; (ii) unique clinical material from high risk patient populations – PJIs will have preferential access to a unique (and increasing) set of clinically annotated biospecimens from HIV+ and HIV- patients with virus-associated cancers collected at the University Medical Center – New Orleans (iii) well-established administrative and cutting edge scientific infrastructure including integrated cancer and HIV clinical trials programs to translate the findings of these projects, advanced core research laboratories, and a new expanded and unique biorepository, the HIV/Clinical Tumor Biorepository (HCTB) Core. Initially, this COBRE brings four projects led by PJIs to study the role of oncogenic viruses such as HPV, KSHV and EBV, as well as, viruses of increasing interest in human carcinogenesis such as human cytomegalovirus (HCMV), human endogenous retrovirus sequences (HERVs), and human neurotropic Polyomavirus JC (JCV). These cancers arise more commonly in the setting of immune deficiencies (including HIV infection), and disproportionately affect African American patients in Louisiana. Implementation of the proposed work will be directed by the following Specific Aims: 1) to establish interdisciplinary teams of investigators and laboratory core infrastructure to support PJI-led research projects on virus-host interactions and their role in pathogenesis of cancer; 2) to develop an administrative infrastructure to mentor and promote the independent career of the PJIs; and 3) to leverage institutional NIH-funded Centers and Programs at the participating institutions to facilitate the integration of PJIs within the clinical and translational research infrastructure. The completion of this program will provide this region with enhanced capabilities to address these and other virus related health problems that may arise in the future.

翻译后摘要：这个COBRE的主要目标是加强在路易斯安那州的生物医学研究基础设施 通过培训有前途的初级研究员（PJIs），他们可以开发针对重大问题的独立研究， 我们地区健康问题。病毒相关癌症仍然是我国发病率和死亡率的主要原因， 这对非洲裔美国人造成了不成比例的影响。这些包括HPV相关的宫颈， 肛门生殖器癌和头颈癌，KSHV相关的卡波西肉瘤和原发性渗出性淋巴瘤， HCV和HBV相关的肝癌和其他癌症，所有这些在我们地区都非常普遍。 这些疾病增加的部分原因可能是， 地区此外，我们的数据还表明，细胞与一种以上的病毒共感染促进或 与恶性转化有关。因此，了解特定病毒和病毒共同作用的方式， 感染促进恶性肿瘤的发展对于确定和实施新的 预防、诊断和治疗战略。因此，培训一支新的调查人员队伍， 在病毒肿瘤学领域进行新的研究对我们国家至关重要。这将是完成 通过建立转化病毒肿瘤学中心（CTVO），利用现有资源， 培训新的研究人员，开发新的实验室基础设施，并支持旨在 在我们独特的人群中研究这些疾病。CTVO将支持科学、指导和 通过提供（i）由NIH资助的经验丰富的指导团队， 国际公认的调查人员，致力于指导PJIs开发尖端的 研究，确保他们的成功培训，并支持他们作为独立研究人员的发展; (ii)来自高风险患者人群的独特临床材料- PJIs将优先获得独特的 (and来自HIV+和HIV-患者的临床注释生物标本集， 癌症收集在大学医学中心-新奥尔良（三）完善的行政和 尖端的科学基础设施，包括综合癌症和艾滋病毒临床试验计划， 这些项目的发现，先进的核心研究实验室，以及一个新的扩大和独特的 HIV/临床肿瘤生物库（HCTB）核心。最初，这个COBRE带来了四个项目， 通过PJIs研究致癌病毒如HPV，KSHV和EBV的作用，以及增加的病毒 对人类致癌作用如人巨细胞病毒（HCMV）、人内源性逆转录病毒 序列（HERV）和人嗜神经性多瘤病毒JC（JCV）。这些癌症更常见于 免疫缺陷（包括艾滋病毒感染）的设置，并不成比例地影响非洲裔美国人 路易斯安那州的病人建议工作的实施将遵循以下具体目标：1） 建立跨学科的研究人员团队和实验室核心基础设施，以支持PJI领导的 研究病毒与宿主的相互作用及其在癌症发病机制中的作用; 2）发展一个 行政基础设施，以指导和促进PJIs的独立职业生涯;以及3）利用 参与机构的机构NIH资助的中心和项目，以促进 临床和转化研究基础设施内的PJIs。该计划的完成将提供 该地区有更强的能力来解决这些和其他可能出现的与病毒有关的健康问题， 在未来